WHO study says remdesivir did not cut hospital stay or mortality in COVID-19 patients
Sharenet,
(Changes sourcing, adds Gilead comment) Oct 15 (Reuters) – Gilead Sciences Inc’s remdesivir had little or no effect on COVID-19…
(Changes sourcing, adds Gilead comment) Oct 15 (Reuters) – Gilead Sciences Inc’s remdesivir had little or no effect on COVID-19…
El medicamento antiviral remdesivir tiene «poco o ningún efecto en la mortalidad de los pacientes hospitalizados» con covid-19.
(Reuters) - Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances…
* Gilead disputes conclusions from WHO trial * Data suggest little or no benefit on survival * WHO trial found little or no…
Topline The antiviral drug remdesivir had little or no effect in treating patients hospitalized with Covid-19, according to a…
By, Clare Wilson, Jessica Hamzelou, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool Milan Jaros/Bloomberg via Getty…